 |
Cyclosporine 2% ophthalmic ointment |
|---|---|
| Trade Name | |
| Orphan Indication | Patients at high risk of graft rejection following penetrating keratoplasty |
| USA Market Approval | USA |
| USA Designation Date | 1991-08-01 00:00:00 |
| Sponsor | Allergan, Inc.;2525 Dupont Drive, P. O. Box 19534;Irvine, California, 92612 |
